PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28481288-4	2017	Results showed that a combination of CL316,243 and rosiglitazone significantly upregulated the expression of the core thermogenic gene Ucp1 as well as genes related with mitochondrial function (Cidea, Cox5b, Cox7a1, Cox8b, and Cycs), compared with the treatment of CL316,243 or rosiglitazone alone.	Rosiglitazone	51-64	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	135-139	
32248079-8	2020	Combined treatment with rosiglitazone and FGF21 resulted in a synergistic increase in Ucp1 mRNA levels both in vitro and in vivo.	Rosiglitazone	24-37	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	86-90	
31317231-7	2019	Moreover, the administration of rosiglitazone, SIS3 and the selective beta3 adrenergic receptor agonist CL316,243 to DIO mice reduced the amount of body-fat deposits (body weight from day 0 to 14, 12.3% reduction), concomitant with morphological changes in white adipose tissue, an increase in mitochondrial biosynthesis and a marked induction of uncoupling protein 1 (UCP1).	Rosiglitazone	32-45	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	347-367	
31317231-7	2019	Moreover, the administration of rosiglitazone, SIS3 and the selective beta3 adrenergic receptor agonist CL316,243 to DIO mice reduced the amount of body-fat deposits (body weight from day 0 to 14, 12.3% reduction), concomitant with morphological changes in white adipose tissue, an increase in mitochondrial biosynthesis and a marked induction of uncoupling protein 1 (UCP1).	Rosiglitazone	32-45	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	369-373	
29910772-5	2018	Adipocytes from inguinal WAT display maximal UCP1 expression and mitochondrial uncoupling only when treated with a combination of the PPARgamma activator rosiglitazone and a beta3-adrenoceptor agonist.	Rosiglitazone	154-167	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	45-49	
28970184-5	2018	Treatment of brown adipocytes with rosiglitazone increases uncoupling protein 1 (UCP1) levels, and increases beta3-adrenoceptor mitochondrial function but does not affect glucose uptake responses.	Rosiglitazone	35-48	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	81-85	
28970184-6	2018	In contrast, inguinal white adipocytes only express UCP1 and beta3-adrenoceptors following rosiglitazone treatment, which results in an increase in all beta3-adrenoceptor-mediated functions.	Rosiglitazone	91-104	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	52-56	
11587528-3	2001	In this study we show that changes in MTE-1 mRNA levels as a result of differences between db/db vs db/+ mice or following long-term treatment of db/db mice with rosiglitazone or Wy-14,643 were more closely correlated with changes in UCP-3 than either UCP-1 or UCP-2 mRNA levels in the tissues examined.	Rosiglitazone	162-175	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	252-257	
22087241-4	2011	Furthermore, the absence of PGC-1alpha did not prevent the positive effect of rosiglitazone on mitochondrial gene expression or biogenesis, but it precluded the induction by rosiglitazone of UCP1 and other brown fat-specific genes in white adipose tissue.	Rosiglitazone	174-187	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	191-195	
28240605-5	2017	However, in subcutaneous inguinal fat (iWAT), rosiglitazone markedly induced molecular signatures of brown fat, including the key thermogenic gene Ucp1.	Rosiglitazone	46-59	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	147-151	
28240605-9	2017	However, when Ucp1 was activated by rosiglitazone, or by iWAT browning in cold-exposed or young mice, expression of the B6 version of Ucp1 was no longer defective relative to the 129 version, indicating epigenomic rescue.	Rosiglitazone	36-49	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	14-18	
28240819-5	2017	RESULTS: Rosiglitazone treatment in 3T3-L1 adipocytes promoted mitochondrial biogenesis, UCP1 expression, and mitochondrial uncoupling.	Rosiglitazone	9-22	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	89-93	
24065084-6	2014	Chronic IBMX treatment was indispensable for the enhanced Iso-induced Ucp1 expression, and treatment with additional rosiglitazone (Rosi) for days 0-8 further increased the Ucp1 expression.	Rosiglitazone	117-130	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	173-177	
24065084-6	2014	Chronic IBMX treatment was indispensable for the enhanced Iso-induced Ucp1 expression, and treatment with additional rosiglitazone (Rosi) for days 0-8 further increased the Ucp1 expression.	Rosiglitazone	132-136	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	173-177	
21723971-7	2012	Administration of antidiabetic TZD rosiglitazone, which sensitizes cells to insulin and increases adipocyte metabolic functions, significantly increased both, BAT (UCP1, PGC1alpha, Dio2, beta3AR, Prdm16, and FoxC2) and WAT (adiponectin and leptin) gene expression in marrow of normoglycemic C57BL/6 mice, but failed to increase the expression of BAT, but not WAT, gene markers in diabetic mice.	Rosiglitazone	35-48	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	164-168	
19274054-11	2009	Rosiglitazone increased UCP1 mRNA expression 4.5-fold in the BAT(B) and significantly more, 7.9-fold, in the WAT(B) adipocytes.	Rosiglitazone	0-13	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	24-28	
17434481-6	2007	RSG ameliorated the mitochondrial Hsp60 expression and induced the expression of UCP-1 in both SC and EP fat.	Rosiglitazone	0-3	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	81-86